MTOR and renal cell adenocarcinoma: The European Society for Medical Oncology (ESMO) maintains the guidelines from 2014 regarding medical treatment of RCC [5]: treatment is based either on monotherapy or combined therapy involving TKIs and inhibitors of mammalian target of rapamycin (mTOR).